Elvitegravir is an orally active HIV-1 integrase strand transfer inhibitor (INSTI) used as an antiretroviral medicine in combination with other antiretroviral agents for the treatment of HIV-1 infection.
Elvitegravir inhibits the HIV-1 integrase enzyme, which is essential for the integration of viral DNA into the host-cell genome. By blocking the strand-transfer step of the viral replication cycle, elvitegravir helps prevent the formation of integrated viral DNA.
Elvitegravir is a small-molecule pharmaceutical active ingredient and has the CAS Registry Number 697761-98-1.
Elvitegravir API is a pharmaceutical active ingredient used in the development and manufacture of antiretroviral medicines. It is particularly relevant to HIV-1 integrase inhibitor formulations and pharmaceutical research.
| Parameter | Specification |
|---|---|
| Appearance | White to off-white crystalline powder |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 20 ppm |
| pH (1% Solution) | 2.0 – 4.0 |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |
| Melting Point | 150°C – 154°C |